INVESTORS & MEDIA

News Release

May 2, 2014 at 9:30 AM EDT

Regeneron Announces Upcoming 2014 Investor Conference Presentations

TARRYTOWN, N.Y., May 2, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:

  • Citi Biotech Virtual Conference: "What is Overlooked in Your Pipeline" at 10:00 a.m. Eastern Time on Monday, May 12, 2014 
  • Bank of America Merrill Lynch 2014 Healthcare Conference at 4:40 p.m. Eastern Time (1:40 p.m. Pacific Time) on Wednesday, May 14, 2014
  • UBS Global Healthcare Conference at 4:00 p.m. Eastern Time on Tuesday, May 20, 2014
  • Sanford C. Bernstein's 30th Annual Strategic Decisions Conference at 8:00 a.m. Eastern Time on Wednesday, May 28, 2014
  • Jefferies 2014 Global Healthcare Conference at 8:30 a.m. Eastern Time on Thursday, June 5, 2014
  • Goldman Sachs 35th Annual Global Healthcare Conference at 2:20 p.m. Eastern Time (11:20 a.m. Pacific Time) on Tuesday, June 10, 2014

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. Archived versions of the presentations will be available for 30 days.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.

Contact Information:                             


Manisha Narasimhan, Ph.D. 

Peter Dworkin

Investor Relations 

Corporate Communications

914.847.5126  

914.847.7640          

manisha.narasimhan@regeneron.com  

peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media